-
Mashup Score: 4
Glesatinib had an acceptable safety profile in patients with advanced, pre-treated NSCLC with MET activating alterations. Modest clinical activity was observed, which likely reflects suboptimal drug bioavailability suggested by previously reported Phase I data, and pharmacodynamic findings of lower …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Does real-world evidence have a role in precision oncology? - 6 month(s) ago
Join this insightful webinar as our expert will be discussing the role of real-world evidence in precision oncology. Register today!
Source: iddi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer - 9 month(s) ago
Abstract. Previous studies implicated PRMT5 as a synthetic lethal target for MTAP deleted (MTAP del) cancers, however, the pharmacological characterization of small molecule inhibitors that recapitulate the synthetic lethal phenotype have not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selectivity in HCT116 MTAP del compared to HCT116 MTAP WT cells. MRTX1719 demonstrated dose-dependent anti-tumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts, mouse or human hematopoietic cells. MRTX1719 demonstrated marked anti-tumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder ade
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Sign the Petition - 10 month(s) ago
Eliminate ABIMs MOC requirement
Source: www.change.orgCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
ABC 13 Chief Meteorologist Travis Herzog is taking some days off after a health scare at…
Source: Houston ChronicleCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4BioGPT: generative pre-trained transformer for biomedical text generation and mining - 1 year(s) ago
Abstract. Pre-trained language models have attracted increasing attention in the biomedical domain, inspired by their great success in the general natural langu
Source: OUP AcademicCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Source: New England Journal of MedicineCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 41How Mark Cuban’s prescription drug disruption could save lives - 1 year(s) ago
The development of highly selective and effective treatments that target the cause of chronic myeloid leukemia was nothing short of a therapeutic miracle….
Source: Dallas NewsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Shares of Merrimack Pharmaceuticals, a shuttered drugmaker, more than doubled Wednesday because of a $225 million windfall that it will receive due to the success of a treatment for pancreatic cancer.
Source: STATCategories: Hem/Oncs, Latest HeadlinesTweet
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC contai… https://t.co/PQDKxzhT2u